Nos publications
Converting light emulsion into a creamy foam for psoriasis treatment. A case study with betamethasone dipropionate
AAPS Annual Meeting & Exposition – Denver (USA) - nov 2016
Experience foam for topical drug delivery
nov 2016
Pharmaceutical foams are becoming more popular probably due to more topical medicines being switched to OTC and the need to innovate and differentiate ‘brands’ and an increasing awareness of the importance of formulating to deliver sensorial benefits and positive impact on patient experience and adherence. Gattefossé, as a leading provider of excipients for the pharmaceutical industry, manufactures solubilizers and texturizers for skin drug delivery. In this white paper we give formulation tips for propellant and propellant-free foams with guidelines on how to formulate and select excipients and case studies with model drugs.
Hydrodynamic size characterization of a self-emulsifying lipid pharmaceutical excipient by Taylor dispersion analysis with fluorescent detection
International Journal of Pharmaceutics, Volume 513, Issues 1–2, Pages 262-269 - nov 2016
In this study the size of microemulsion droplets is carried out using Tailor Dispersion Analysis in comparison to Dynamic Light Scattering. The size evolution of a Labrasol® self emulsifying drug delivery system as a function of concentration and temperature is evaluated. The influence of physical parameters and polydispersity is discussed.
Maisine® CC, a unique pharmaceutical oil for solubility and oral bioavailability enhancement
Gattefossé - oct 2016
This white paper features Maisine® CC (glyceryl monolinoleate NF), a unique pharmaceutical oil that has a long and successful history of use in lipid-based formulation for drug solubilization and oral bioavailability enhancement.
Impact of hot and wet granulation techniques on Compritol® 888 ATO lipid matrices for extended release of highly water soluble high dose API
CRS Annual Meeting – Seattle (2016) - 2016
The poster describes the formulation of sustained release tablets with Metformin HCl (a well-known oral antihyperglycemic) using Compritol® 888 ATO as a sustained release agent. Different granulation techniques were evaluated to elucidate the impact of formulation and process on tablet properties and drug release. The objective was to determine a simple process that enables the production of ‘smaller’ tablets, using less excipients, whilst maintaining therapeutic drug dose and obtaining drug release which passes Pharmacopeial specifications.
Pharmaceutical foams with optimized microemulsion and propellant-free pump
PBP World Meeting 2016 – Glasgow (Scotland) - avr 2016
Efficient skin delivery: no compromise with Transcutol®
OutsourcingPharma - nov 2015
This white paper describes Transcutol®, the highest purified pharmaceutical grade of Diethylene Glyceryl monoEthylEther (DEGEE).
Scientific publications asserting the safety of Transcutol® are listed to highlight the non-skin irritant property of Transcutol®. Moreover, solvent properties of Transcutol® are described and solubility data in different solvents are given to illustrate the remarkable solvent capacity of Transcutol®.
This exceptional safety and solvent property make Transcutol® an ideal chemical penetration enhancer for topical formulations, where efficiency and non skin irritancy are key success factors. Examples of commercial uses of DEGEE are cited to illustrate the versatility of use of this excipient in many different topical dosage forms. Practical information is also given for the formulation of Transcutol® in many topical dosage forms.
Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity
International Journal of Pharmaceutics, Volume 495, Issue 1, Pages 385-392 - nov 2015
This article describes the work undertaken in Gattefossé R&D labs (St Priest) to develop lipid formulations for low to medium lipophilicity API: piroxicam, nifedipine and curcumin and evaluate the effect of in-vitro digestion on the solubilizing capacity of the formulations.
Reaching milestones in lipid-based formulations: from effective prediction to successful development
sep 2015
This white paper describes the important milestones achieved in lipid based formulation (LBF) development for oral drug delivery. Collaborative research between academic and industrial partners has increased understanding of the functional properties of lipid excipients and the role they play in solubilizing poorly water soluble compounds. It has also led to the development of in vitro – in vivo predictive analytical tools. The key scientific articles describing these milestones are collected in this one White Paper, providing a single source of practical information for those interested in lipid formulation development.